NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 69 filers reported holding NURIX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $14,621,000 | -44.2% | 1,154,000 | -38.3% | 0.31% | -23.7% |
| Q1 2022 | $26,199,000 | -51.6% | 1,870,000 | 0.0% | 0.41% | -40.8% |
| Q4 2021 | $54,137,000 | +50.6% | 1,870,000 | +55.8% | 0.69% | +46.0% |
| Q3 2021 | $35,952,000 | +12.9% | 1,200,000 | 0.0% | 0.47% | +10.7% |
| Q2 2021 | $31,836,000 | -14.7% | 1,200,000 | 0.0% | 0.43% | -22.6% |
| Q1 2021 | $37,308,000 | +8.1% | 1,200,000 | +14.3% | 0.55% | +4.5% |
| Q4 2020 | $34,524,000 | +98.7% | 1,050,000 | +111.0% | 0.53% | +55.6% |
| Q3 2020 | $17,376,000 | – | 497,740 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |